中紅醫療(300981.SZ):子公司完成醫療器械延續註冊
格隆匯11月25日丨中紅醫療(300981.SZ)公佈,子公司江西科倫醫療器械製造有限公司於近期取得國家藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,上述註冊證為原有產品的延續註冊,該註冊證有效期限由原2024年12月3日到期延續至2029年12月3日到期。產品為一次性使用輸液器帶針,屬於Ⅲ類醫療器械,適用於醫療單位靜脈滴注藥液用。公司表示,註冊證有效期的延長將增強公司及子公司的綜合競爭力,滿足多元化市場需求,有利於進一步提高市場拓展能力。但產品實際銷售情況取決於市場推廣效果,產品銷售及利潤貢獻具有不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.